UOC
BOLD

UBS O'Connor’s Audentes Therapeutics, Inc BOLD Stock Holding History

UBS O'Connor’s Portfolio BOLD Stock Details BOLD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q2 		– Sell
-55,085
Closed -$1.66M – 399
2018
Q1 		$1.66M Buy
+55,085
New +$1.86M 0.03% 199

Other funds holding BOLD

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
VVM
Versant Venture Management San Francisco, California $141M AUM 190.82% 1-Year Est. Return
DM
Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return

UBS O'Connor's BOLD Position: Q2 2018 in Review

UBS O'Connor sold out of Audentes Therapeutics, Inc (BOLD) in Q2 2018, closing a stake of 55,085 shares — an estimated $1.66M sold.

UBS O'Connor first reported a position in BOLD in Q1 2018 and held it in 1 quarter. The position peaked at $1.66M in Q1 2018. 123 funds tracked by Wall St. Rank hold BOLD as of Q2 2018.

  • UBS O'Connor reported no remaining Audentes Therapeutics, Inc position as of Q2 2018 after selling out during the quarter.
  • UBS O'Connor sold 55,085 Audentes Therapeutics, Inc shares in Q2 2018, an estimated $1.66M.
  • UBS O'Connor first reported a position in Audentes Therapeutics, Inc in Q1 2018 and held it in 1 quarter.
  • UBS O'Connor's Audentes Therapeutics, Inc position peaked at $1.66M in Q1 2018.
  • 123 funds tracked by Wall St. Rank held Audentes Therapeutics, Inc as of Q2 2018.

Based on UBS O'Connor's 13F filing for Q2 2018, filed 14 Aug 2018.